Stockwinners Market Radar for May 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:29 EDT Syntec Optics to go public via merger with OmniLit Acquisition Corp. - Syntec Optics has entered into a definitive business combination agreement with OmniLit Acquisition Corp. Upon or following closing, OmniLit will be renamed Syntec Optics Holdings, and listed on Nasdaq under the new ticker "OPTX." The board of directors and the special committee of independent directors of OmniLit unanimously approved the transactions contemplated by that certain Agreement and Plan of Merger, dated May 9.

18:23 EDT Quanta Services COO sells $8.56M in common stock - In a regulatory filing, Quanta Services disclosed that its COO James Probst sold 50K shares of common stock on May 10th in a total transaction size of $8.56M.

18:14 EDT Soros Fund buys American Water, exits D.R. Horton in Q1 - George Soros' Soros Fund Management disclosed in a 13F SEC filing its holdings as of March 31, 2023. The fund's 39 new buys during the fourth quarter included, by size of position, American Water (AWK), iShares Russell (IWM), AerCap Holdings (AER), KraneShares CSI China Internet ETF (KWEB), and iShares MSCI Emerging Markets ex China ETF (EMXC). Soros exited 48 positions during the quarter, including by size of previous position D.R. Horton (DHI), TransDigm Group (TDG), Columbia Banking System (COLB), and Tesla (TSLA). The fund increased its stake in 17 holdings, including by size of previous position Horizon Therapeutics (HZNP), Nike (NKE), Interactive Brokers (IBKR), Uber (UBER), and Estee Lauder (EL). Soros reduced its stake in 26 holdings, including by size of previous position Rivian (RIVN), Aramark (ARMK), First Horizon (FHN), Bowlero (BOWL), and Salesforce (CRM). The fund's top holdings as of December 31, in order of size, were Horizon Therapeutics, iShares iBoxx $ Investment Corporate Bond ETF, Alphabet Class A (GOOGL), First Horizon Corp, and Liberty Broadband (LBRDA).

17:22 EDT Tyson Foods CEO buys $500K in common stock - In a regulatory filing, Tyson Foods disclosed that its CEO Donnie King bought 10.4K shares of common stock on May 11th in a total transaction size of $500K.

17:07 EDT Aligos Therapeutics enters research collaboration with Xiamen Amoytop Biotech - Aligos Therapeutics announced that it has entered into a research collaboration and development agreement with Xiamen Amoytop Biotech Co. for the use of Aligos' oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory. Under the terms of the agreement, Aligos and Amoytop will collaborate on the research and development of oligonucleotide compounds for the treatment of liver diseases. Amoytop will receive an option to obtain an exclusive license to develop and commercialize the resultant products in the Greater China territory while Aligos will retain rest-of-world rights. Aligos will also receive an upfront payment and research collaboration funding and be eligible to receive up to a total of $109M in development and sales milestone payments for licensed products as well as tiered royalties on net sales.

16:40 EDT Masonite names Katie Shellabarger as Chief Accounting Officer - Masonite "announced that Katie Shellabarger has been appointed as Vice President & Chief Accounting Officer effective May 11, 2023."

16:25 EDT Bentley Systems CEO sells $5.9M in common stock - In a regulatory filing, Bentley Systems disclosed that its CEO Gregory Bentley sold 129.7K shares of common stock on May 10th in a total transaction size of $5.9M.

16:16 EDT Sarcos Technology names Laura Peterson as interim CEO - Sarcos Technology and Robotics announced the appointment of Laura Peterson as its interim president and chief executive officer, effective immediately. Peterson will replace outgoing president and CEO, Kiva Allgood. Sarcos thanks Ms. Allgood for her service and wishes her well in her new endeavors. Peterson, who currently serves on the Sarcos Board of Directors, brings an extensive understanding of the strategic considerations and challenges associated with complex, technology-intensive global industries. Her career and corporate board experience span multinational industrial, high-growth technology, and transportation sectors.

15:46 EDT Musk says 'bringing on Linda allows me to devote more time to Tesla' - In reply to a Twitter user asking Elon Musk to confirm he is not stepping down from being the CEO of Tesla (TSLA), Musk tweeted: "Obviously, bringing on Linda allows me to devote more time to Tesla, which is exactly what I will be doing!" Earlier today, Musk had confirmed that Linda Yaccarino has agreed to join as the new CEO of Twitter. Reference Link

14:12 EDT FDA approves Astellas' Veozah to treat hot flashes caused by menopause - The U.S. Food and Drug Administration approved Veozah, an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. "Veozah is the first neurokinin 3 receptor antagonist approved by the FDA to treat moderate to severe hot flashes from menopause. It works by binding to and blocking the activities of the NK3 receptor, which plays a role in the brain's regulation of body temperature," the FDA stated. The FDA granted the Veozah application Priority Review designation. The approval of Veozah was granted to Astellas Pharma US, Inc. Reference Link

13:45 EDT ImmunoPrecise Antibodies teases 'something exciting' coming next week - Earlier, ImmunoPrecise Antibodies tweeted: "Get ready - something exciting is coming next week" from its official corporate Twitter account. Reference Link

13:26 EDT Harbor Custom Development Inc trading resumes

13:16 EDT NYSE to bust all trades in Top Financial between 9:30-10:09 ET today - In a trader notice, the NYSE announced: "NYSE Group Equities Exchanges in conjunction with other UTP exchanges, have ruled to bust all trades in TOP - TOP Financial Group Limited, executed between 9:30:00 - 10:09:00 ET today. This ruling is not eligible for appeal." Reference Link

13:01 EDT Baker Hughes reports U.S. rig count down 17 to 731 rigs - Baker Hughes reports that the U.S. rig count is down 17 from last week to 731 with oil rigs down 2 to 586, gas rigs down 16 to 141 and miscellaneous rigs up 1 to 4. The U.S. Rig Count is up 17 rigs from last year's count of 714 with oil rigs up 23, gas rigs down 8 and miscellaneous up 2. The U.S. Offshore Rig Count is up 1 to 22, up 4 year-over-year. The Canada Rig Count is up 1 from last week to 94, with oil rigs up 3 to 37, gas rigs down 2 to 57. The Canada Rig Count is up 6 rigs from last year's count of 88 with oil unchanged, gas rigs up 6.

12:33 EDT Telus becomes official major partner of CF Montreal - CF Montreal announced that TELUS has become one of the Club's major partners effective immediately through to 2027. The new multi-year partnership also coincides with the Club's 30th anniversary, which will be celebrated throughout the upcoming 2023 season, and brings together two organizations with a proven and shared commitment to drive meaningful change in their local communities. Through this partnership, TELUS and CF Montreal will support thousands of youth by providing free access to soccer camps and encouraging the development of athletes with sport bursaries.

12:29 EDT QuantaSing Group Ltd- ADR trading resumes

12:00 EDT Youdao falls -13.5% - Youdao is down -13.5%, or -85c to $5.47.

12:00 EDT Dingdong falls -19.3% - Dingdong is down -19.3%, or -78c to $3.26.

12:00 EDT Ouster rises 19.5% - Ouster is up 19.5%, or 75c to $4.59.

11:55 EDT Musk confirms Linda Yaccarino hired as new CEO of Twitter - Tesla (TSLA) CEO Elon Musk tweeted: "I am excited to welcome Linda Yaccarino as the new CEO of Twitter! @LindaYacc will focus primarily on business operations, while I focus on product design & new technology. Looking forward to working with Linda to transform this platform into X, the everything app." Reference Link

11:30 EDT Data Storage secures seven-figure order with Forbes Global 2000-listed company - Data Storage Corporation announced that its wholly owned subsidiary, Flagship Solutions Group, has secured a multi-million-dollar order with a Forbes Global 2000 listed company. "We are thrilled to be expanding our relationship with this existing customer, which has resulted in a seven-figure order," commented Tom Kempster, President of Flagship.

11:22 EDT Jupiter Wellness Acquisition Corp trading halted, volatility trading pause

11:03 EDT Inter&Co Securities approved by FINRA to operate as U.S. broker - Inter&CO Securities, a subsidiary of Inter&Co, has been granted approval by the Financial Industry Regulatory Authority to operate as an investment broker in the United States. "Now, with US brokerage capabilities, Inter can provide more investment opportunities for customers and this expands the accessibility of the company's investment portfolio products from Brazil to the United States," said Inter&Co's CEO Joao Vitor Menin. "We were the first Brazilian company in the financial sector to enable direct international investments, seamlessly integrated within our Super App used in Brazil, and now wish to grow our successful platform in the United States with a thoughtful, measured approach."

10:48 EDT SiriusPoint acknowledges Dan Loeb's decision to conclude transaction talks - SiriusPoint acknowledged the decision by Daniel Loeb and certain affiliates to conclude discussions regarding a potential transaction to acquire the company. Following public disclosure of Mr. Loeb's interest in acquiring SiriusPoint on April 12, the board formed a Special Committee, which included all non-executive directors of the board excluding Mr. Loeb, to consider any acquisition proposals made by Mr. Loeb. The Committee issued the following statement: "The Committee and management team are committed to acting in the best interests of the company and all shareholders. To that end, the Committee, in consultation with its independent financial and legal advisors, engaged in exploratory discussions with Mr. Loeb regarding a potential transaction. Ultimately, the Committee was unanimous in its belief that its current strategy is the best path to deliver enhanced long-term value for shareholders. The company has made significant progress during the last seven months to improve underwriting performance, reduce volatility and rebalance its investment portfolio towards high-quality fixed-income assets. This was evidenced by its strong first quarter results reported on May 3, 2023. SiriusPoint acknowledges Mr. Loeb's support for the company's management team and strategy."

10:25 EDT Sarepta halted as FDA panel weighs DMD gene therapy - Shares of Sarepta Therapeutics are halted for news pending while the company's gene therapy candidate for Duchenne muscular dystrophy faces an FDA panel vote today.

10:10 EDT TOP Financial Group Ltd trading halted, news pending

10:00 EDT SiriusPoint falls -9.7% - SiriusPoint is down -9.7%, or -97c to $8.99.

10:00 EDT Ranpak Holdings rises 14.4% - Ranpak Holdings is up 14.4%, or 44c to $3.48.

10:00 EDT Arlo Technologies rises 18.2% - Arlo Technologies is up 18.2%, or $1.28 to $8.33.

09:47 EDT IonQ falls -9.5% - IonQ is down -9.5%, or -67c to $6.36.

09:47 EDT Embraer rises 5.2% - Embraer is up 5.2%, or 72c to $14.44.

09:47 EDT Ranpak Holdings rises 11.6% - Ranpak Holdings is up 11.6%, or 35c to $3.39.

09:42 EDT Francisco Partners completes acquisition of Sumo Logic - Sumo Logic announced that Francisco Partners has completed its acquisition of the company. Pursuant to the terms of the definitive agreement announced on February 9, 2023, Francisco Partners has acquired all outstanding shares of Sumo Logic common stock for $12.05 per share in cash, valuing the company at an aggregate equity valuation of approximately $1.7B. As a result of the completion of the transaction, Sumo Logic's common stock has ceased trading and is no longer listed on the NASDAQ stock exchange.

09:38 EDT TOP Financial Group Ltd trading halted, volatility trading pause

09:32 EDT FingerMotion enters cooperation agreement with Migu Video - FingerMotion entered into a cooperation agreement between Migu Video Technology and FingerMotion's contractually controlled subsidiary, Shanghai JiuGe Information Technology to start in-depth collaboration on overseas hardware and terminal business. Migu Video is a wholly-owned subsidiary of China Mobile's Migu Culture Technology, which is the sole streaming content producer of Migu Culture in the video field. It is regarded as the first to establish a Multi-channel network in China. Overseas growth is an essential element of the MCN of Migu Video. Another key element is the research and development of international standards that highlight Chinese culture and art. The final element is the establishment of an international video sharing platform. Through this cooperation agreement the Company seeks to collaborate with Migu Video to develop a solution to fully combine the Company's innovative product research & development capabilities and resource integration capabilities in order to expand into the international streaming market with Migu Video. This cooperation agreement sets the stage for FingerMotion to build synergies in the development of an international streaming content aggregator and highlight FingerMotion's brand differentiation advantages in international markets. This cooperation agreement will help FingerMotion implement its strategic plan of "domestic precision and overseas extension" in 2023. The initial focus will be on Migu Video, ensuring that its entire network of users, which currently exceeds 100 million, can see the optionality and customizable options of Migu Video. In a subsequent phase of the collaboration with Migu Video, the two parties plan to focus on establishing a sales organization, product optimization, and portal upgrade in expectation of bringing more innovative services to customers while continuously improving the social value of the overseas hardware and terminal business. Within the next two years, the Company and Migu Video anticipate that they will serve more than 10 million overseas users and more than 10 overseas countries, and the Company intends to gradually expand its own sub-brands with overseas hardware and terminal as a core line of business.

09:29 EDT First Solar announces acquisition of Evolar, to pay $38M at closing - First Solar earlier announced that it has acquired Evolar AB, a European company engaged in perovskite technology. The purchase price is approximately $38M paid at closing and up to an additional $42M to be paid subject to certain technical milestones being achieved in the future. The impact to 2023 operating expenses is expected to be approximately $2M-$4M, excluding the impact of purchase price accounting. "With this acquisition, along with our new innovation center in the United States and longstanding commitment to R&D, we are investing not just in First Solar's future, but the future of solar energy," said Mark Widmar, CEO First Solar. Under the agreement, the terms of which were not disclosed, Evolar's laboratory in Uppsala, Sweden, will continue to conduct research activity, marking the first time that First Solar will have an R&D facility in Europe. Upon closing of the transaction, approximately 30 of Evolar's R&D staff will transition to First Solar, working in close collaboration with the company's team of about 60 scientists at its advanced research technology center in Santa Clara, California, and the development teams in Perrysburg, Ohio.

09:21 EDT NBCUniversal announces Linda Yaccarino leaving company, effective immediately - Comcast's (CMCSA) NBCUniversal announced that Linda Yaccarino is leaving the company, effective immediately. Mark Marshall, currently President, Advertising Sales and Client Partnerships, will become interim Chairman of NBCUniversal's Advertising and Partnerships group, reporting to Mark Lazarus, Chairman, NBCUniversal Television and Streaming. Mike Cavanagh, President of Comcast Corporation said, "We are grateful for Linda Yaccarino's leadership of NBCUniversal's Advertising Sales business, and for the innovative team and platform she has built. Linda has made countless contributions to the company during her twelve year tenure, and we wish her the best." The Wall Street Journal has reported that Yaccarino is in talks to become the next CEO of Twitter (TWTR) after Elon Musk announced that his role will shift to executive chairman and chief technology officer at the micro-blogging service operator. Reference Link

09:15 EDT Charles Schwab reports April total client assets up 5% from last year - The Charles Schwab Corporation released its Monthly Activity Report today. Company highlights for the month of April 2023 include: Total net new assets brought to the company by new and existing clients in April 2023 totaled $13.6 billion, while core net new assets equaled negative $2.3 billion. These flows reflect client cash disbursements during tax season. Total client assets were $7.63 trillion as of month-end April, up 5% from April 2022 and up 1% compared to March 2023. Active brokerage accounts reached 34.2 million in April, up 1% from April 2022 and flat compared to March 2023. Chief Financial Officer Peter Crawford commented, "As previously noted in my commentary published on May 5, 2023, April marked the third consecutive month of deceleration in the daily average pace of cash realignment within bank sweep deposits and Bank Deposit Account (BDA) balances. This trend has continued into May, with the month-to-date pace improving nearly 50% versus April. We remain confident that client cash realignment activity will abate during 2023 - helping client cash on the balance sheet resume growing in proportion with the growth in total client assets over time."

09:13 EDT Momentus signs launch service agreement with SpaceX - Momentus signed a contract with SpaceX to reserve a port on its Transporter-12 mission targeted for launch no earlier than October 2024. With this agreement, Momentus is planning on flying on three missions with SpaceX in 2024, inclusive of every Transporter rideshare mission slated for next year: Transporter-10 mission targeting launch no earlier than January 2024; Transporter-11 mission targeting launch no earlier than June 2024; Transporter-12 mission targeting launch no earlier than October 2024. "This launch schedule enables us to meet the anticipated demand for our services," said Momentus Chief Commercial Officer Chris Kinman. "Providing mission management and integration services is just the starting point for the work Momentus does, and we're happy to accommodate our customers with speed, affordability, and flexibility both in getting to space and in executing their missions once in orbit."

09:10 EDT Hoth Therapeutics Inc trading resumes

09:07 EDT IGM Biosciences expects cash to fund operations into 4Q24 - The Company expects full year 2023 GAAP operating expenses of $275 million to $285 million, including estimated non-cash stock-based compensation expense of approximately $45 million, and full year collaboration revenue of approximately $3 million related to the Sanofi agreement. The Company expects to end 2023 with a balance of more than $200 million in cash and investments, and for the balance to enable it to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2024.

09:05 EDT Liquid Media adjourns Special Meeting - Liquid Media Group is announcing the adjournment of the special meeting of shareholders previously scheduled for May 12, 2023, to rather be held on May 26, 2023 at 2:00pm PT at Suite 401, 750 West Pender Street, Vancouver, BC V6C 2T7 Canada.

09:05 EDT Bit Origin mines 27 bitcoins in April - Operation Update: As of April 30, 2023, the total mining hash rate stands at 403 PH/s with 4,250 miners installed in the Indiana facility, representing all miners the Company has purchased. Bitcoin Production and Revenue: The Company mined 27.0 Bitcoins and achieved a revenue of $778,640 in April 2023. Mining Sites Development: As of April 30, 2023, the Company has one hosting mining site in operation and one mining site under development. The Company ceased its operation in the mining facility in Georgia from December 31, 2022. Site One - Marion, IN, 5.3 Megawatts: On June 8 and July 11, 2022, the Company announced that it entered into two hosting service agreements to increase mining capacity by 3 MW and 2.3 MW, respectively. Based on mutual understanding and arrangements, the Company further expanded its capacity in the Indiana mining facility, and as of April 30, 2023, 4,250 miners at this site have been deployed. Site Two - Cheyenne, WY, 45MW: On June 15, 2022, the Company announced that it entered into a set of definitive agreements with a private cryptocurrency mining investment fund. The Fund is investing in a mining site in Wyoming, U.S. with a capacity of up to 75 MW. Phase I of the Project of a capacity of up to 45MW for the mining facility in Wyoming was energized in March 2023, and construction of Phase II of 25MW is expected to commence in mid-May 2023.

09:03 EDT Clearmind Medicine announces IRB approval to conduct AUD trial - Clearmind Medicine has received Ethics Committee approval for its CM-CMND-001 Phase I/II clinical trial of its MEAI-based CMND-100 compound for the treatment of alcohol use disorder at Israel's IMCA center. CM-CMND-001 is a multinational, multi-center, single and multiple dose tolerability, safety and pharmacokinetic Study of CMND-100 in healthy volunteers and AUD subjects. The Israeli study will be led by Prof. Mark Weiser, M.D., head of the Psychiatric Division at the Sheba Medical Center in the Tel Aviv suburb of Ramat Gan. The company intends to have two additional sites in the United States, for this study, subject to signing an agreement with local sites. The primary end point of the clinical trial is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated doses of CMND-100 in healthy subjects and those with AUD. The secondary end point is to evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving, in individuals with moderate-to-severe AUD. Oral capsules will be administered once daily, for ten consecutive days. The patients will report their drinking patterns and craving for alcohol (and cigarettes) during the clinical trial period.

09:02 EDT Novavax Covid vaccine gets extended authorization for adolescents in Singapore - Novavax announced that the Singapore Health Sciences Authority has granted extended interim authorization and the Ministry of Health has included Nuvaxovid into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent Covid.

09:02 EDT Cutera comments on termination of poxy solicitation by Voce Capital - Cutera commented on the termination of the proxy solicitation by Voce Capital Management with respect to the Special Meeting of Stockholders, scheduled for June 9, 2023. Cutera issued the following statement: The Special Committee of the Cutera Board of Directors deeply values the constructive engagement we have had with our stockholders over recent weeks. The Board refreshment we announced on May 9, 2023, followed an agreement with two of our largest stockholders, which collectively own more than 15% of the Company's outstanding shares. The four new independent directors were selected by the Special Committee after a comprehensive process of identifying, vetting and interviewing candidates. The Special Committee notes that two of its five members have decided not to stand for reelection at the 2023 Annual Meeting. The remaining three members were appointed to the Board in the past two years, and with approval of Voce Capital's J. Daniel Plants in his then-capacity as Executive Chairman of the Board. The Special Committee will continue to take action that is in the best interest of Cutera and all stakeholders. The Company separately announced that it has also resolved its dispute with former Chief Executive Officer David Mowry. Mowry resigned from the Company's Board with immediate effect, will be available to support the CEO transition and will withdraw from his participation in Mr. Plants' litigation against Cutera. Mowry has also withdrawn his demand for the Special Meeting.

08:52 EDT Bit Brother announces new mining servers in Texas farm are in full operation - Bit Brother announced that the newly purchased 1.5MW mining servers installed in its first Texas mining farm are in full operation and are located at 1968 N Access Rd, Clyde, TX 79510. The total number of installed servers in the first mining farm has reached 1,750 with aggregated computing power of 175,000TH/S, thus reaching its fully loaded capacity of 6MW. The company estimates that theservers can generate a total value of 0.5 BTC per day, and 15 BTC per month, assuming that all the machines are functioning as expected.

08:46 EDT Orbit International announces further delay in filing 2022 annual report - Orbit International announced that the filing of its 2022 Annual Report has been further delayed with the OTC as additional time is needed to complete the audit of the acquired and ending inventory of its recently acquired Simulator Product Solutions LLC subsidiary and the preparation of the 2022 Annual Report. The company said, "As a result of this late filing, our stock will be moved, effective Tuesday, May 16, 2023, to the OTC Expert Market, an illiquid market, and will remain there until our Annual Report is completed and the Company is reinstated to the OTC Pink Market. In addition, the Company will suspend its buyback program while it remains on the OTC Expert Market and will reinstate its buyback program when it returns to the OTC Pink Market."

08:39 EDT Adial Pharmaceuticals expects cash to fund operations into 1Q24 - As of March 31, 2023, cash and cash equivalents were $2.3 million compared to $4.0 million as of December 31, 2022. The Company believes that its existing cash and cash equivalents, as well as the impact of the recently announced agreement to sell its Purnovate's Assets and Business, will fund its operating expenses into the first quarter of 2024. Under the agreement, the Company will receive non-dilutive funding and the sale has significantly reduced its current cash burn rate.

08:36 EDT SAB Biotherapeutics announces publication of SAB-183 nonclinical data - SAB Biotherapeutics announced the publication of nonclinical data in the medical journal Antibodies. The data are from a study conducted in collaboration with the United States Army Medical Research Institute of Infectious Disease highlighting that fully-human immunoglobulins derived from Tc bovines can protect mice from Yersinia pestis, a Tier 1 select bacterial biothreat agent that can rapidly cause fatal infections and is associated with pneumonic plague as well as bubonic plague. The article, "Polyclonal antibodies derived from transchromosomic bovines vaccinated with the recombinant F1-V vaccine increase bacterial opsonization in vitro and protect mice from pneumonic plague," was published online in the 10th anniversary special issue of Antibodies. SAB-183, the Tc bovine derived fully-human immunoglobulin, demonstrated increased opsonization and phagocytosis of Y. pestis in vitro and elicited a strong immune response with significant protection to mice exposed to Y. pestis in vivo. Y. pestis is a major biothreat due to its capacity for aerosol dissemination and its highly contagious nature in the pneumonic form. Furthermore, as the study notes, drug-resistant isolates of Y. pestis are on the rise and constitute a significant concern for the public health and biodefense communities. In lieu of any approved vaccine for this pathogen, effective antibody therapies and other countermeasures are needed to ensure preparedness. This study confirmed that rapid production of antibodies from Tc bovines provides broad protection against plague and other bacterial or viral infections and can be used to produce treatments to counter the challenges of antibiotic resistance and rapid mutation of pathogens. In contrast to monoclonal antibodies, polyclonal antibodies derived from Tc bovines afford greater epitope coverage, which may mitigate loss of efficacy against a mutating pathogen and emergence of escape mutants. Study researchers characterized and evaluated anti-plague fully human immunoglobulin generated in Tc bovines using functional macrophage assays in vitro and in vivo mouse models of pneumonic plague. The study authors concluded that fully-human immunoglobulin, which has shown preclinical and clinical efficacy against other pathogens, including SARS-CoV-2, influenza, and C. difficile, could potentially be used to develop a polyclonal plague countermeasure using F1, LcrV and/or their antigens in combination. This publication marks the first study data that have been announced for SAB-183.

08:33 EDT BitNile Metaverse announces 1-for-30 reverse stock split - BitNile Metaverse announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on May 15, 2023. The reverse stock split was previously approved by the Board of Directors of BitNile in accordance with Nevada law, under which no stockholder approval is required, and is intended to increase the per share trading price of BitNile's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. BitNile's common stock will continue to trade on the NASDAQ Capital Market under the symbol "BNMV" and under a new CUSIP number, 27888N406. As a result of the reverse stock split, every thirty pre-split shares of common stock outstanding will become one share of common stock. The reverse stock split will also proportionately reduce the number of shares of authorized common stock from 100 million to 3,333,333 shares. The reverse split will also apply to common stock issuable upon the exercise of BitNile's outstanding convertible securities. BitNile's transfer agent, Pacific Stock Transfer Company, which is also acting as the exchange agent for the reverse split, will provide instructions to shareholders regarding the process for exchanging share certificates. Any fractional shares of common stock resulting from the reverse stock split will be rounded up to the nearest whole post-split share and no shareholders will receive cash in lieu of fractional shares.

08:32 EDT Maris-Tech receives purchase order for $410,000 from Israeli defense company - Maris-Tech had received a repeat purchase order for $410,000 of Neptune XMC from a leading Israeli provider of defense products and services. Neptune XMC is a dual channel HD-SDI and Quad SD recording, streaming, and data acquisition platform, a key component for mission computers. The product is operational in various applications worldwide. Maris-Tech expects to deliver the order during 2023.

08:31 EDT Freeline completes ADS ratio change - Freeline Therapeutics announced that the company's previously disclosed change to its American Depositary Share to ordinary share ratio has been made effective prior to the open of business on May 12, 2023. The ratio has changed from one ADS to one ordinary share to the new ratio of one (1) ADS to fifteen ordinary shares. For the company's ADS holders, the change in the ADS ratio has the same effect as a one-for-fifteen reverse ADS split and is intended to enable the company to regain compliance with the Nasdaq minimum bid price requirement. At the effective time of the ratio change, all ADSs then held were canceled and new ADSs were issued, whereby for every fifteen ADSs canceled, one new ADS was issued. Holders of uncertificated ADSs had their ADSs automatically exchanged.

08:30 EDT Cumulus Media announces modified dutch auction tender up to $10M - Cumulus Media commenced a "modified Dutch auction" tender offer to purchase up to $10 million of shares of its Class A common stock, or such lesser number of shares of its Class A common stock as are properly tendered and not properly withdrawn, at a price not greater than $3.25 and not less than $2.85 per share of Class A common stock, to the tendering shareholder in cash, less any applicable withholding taxes and without interest. The Offer is made upon the terms and subject to the conditions described in the offer to purchase and in the related letter of transmittal. The Offer begins today, May 12, 2023, and will expire at Midnight, New York City time, at the end of the day, on June 9, 2023, unless extended or earlier terminated by Cumulus. Cumulus is conducting the Offer by means of a procedure commonly called a "modified Dutch auction." This procedure allows shareholders to select the price, within a price range specified by Cumulus, and the number of shares they are willing to sell at that price. The Offer is being made under Cumulus's previously announced $50 million share repurchase program. The purchase price will be the lowest price per share of not greater than $3.25 and not less than $2.85 per share, at which shares have been properly tendered and not properly withdrawn, that will enable Cumulus to purchase the maximum number of shares having an aggregate purchase price not exceeding $10 million. Promptly after the Expiration Date, Cumulus will, on the terms and subject to the conditions described in the offer to purchase, determine the single per-share purchase price that Cumulus will pay, subject to proration and conditional tender provisions, for shares properly tendered at or below the purchase price in the Offer and not properly withdrawn, and accepted for payment, taking into account the number of shares tendered pursuant to the Offer and the prices specified, or deemed specified, by the tendering shareholders. Cumulus believes that the repurchase of shares pursuant to the Offer is consistent with its goal of maximizing shareholder value. Additionally, Cumulus believes that the "modified Dutch auction" tender offer construct represents an efficient mechanism to provide its shareholders with the opportunity to tender all or a portion of their shares in order to obtain liquidity without the potential disruption to the share price that can result from open market sales. Shareholders who choose not to tender, or those who retain an equity interest in the Company as a result of a partial or conditional tender of shares or proration, may own a greater percentage ownership of the Company's outstanding shares following the consummation of the Offer.

08:27 EDT Scynexis reports closing exclusive BREXAFEMME license agreement with GSK - SCYNEXIS announced the closing of its previously announced exclusive license agreement with GSK to commercialize the novel antifungal BREXAFEMME as a treatment for vulvovaginal candidiasis and further develop ibrexafungerp for multiple indications in invasive and life-threatening fungal diseases. Under the terms of the agreement, GSK will make an upfront payment to SCYNEXIS of $90 million, plus additional potential milestone-based payments totaling up to $503 million. GSK will also pay mid-single digit to mid-teen digit tiered royalties on the totality of sales across all indications. Further information regarding the financial terms of the agreement can be found in SCYNEXIS's SEC filings. GSK has the rights to develop ibrexafungerp and commercialize BREXAFEMME in all countries except the greater China region and certain other countries already out-licensed by SCYNEXIS to third parties. Under the license agreement, SCYNEXIS will continue executing the Phase 3 program for invasive candidiasis and other ongoing trials. SCYNEXIS retains rights to all other assets in its proprietary class of enfumafungin-derived antifungal compounds, which are currently in preclinical development for the treatment of life-threating invasive fungal diseases. As part of this exclusive license agreement, GSK has been granted a right of first negotiation to these compounds.

08:24 EDT BiomX appoints Jason Marks, Michael Dambach to board of directors - BiomX announced the appointments of Jason Marks and Michael Dambach to its Board of Directors. Mr. Marks most recently served as Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary, and as Senior Advisor, with Amarin Corporation. Mr. Dambach has over two decades of experience in the life sciences and financial services sectors and currently serves as Vice President and Treasurer of Biogen.

08:19 EDT ReTo Eco-Solutions postpones date for share combination - ReTo Eco-Solutions announced that its common shares will begin trading on a post-share combination basis on the Nasdaq Capital Market on May 15, instead of May 12, as previously announced. On May 9, 2023, ReTo's Board of Directors approved a 10:1 share combination of its common shares. As a result of the Share Combination, each ten pre-split shares of the Company's common shares will automatically combine into one common share without any action on the part of the holders, the Company's authorized shares will be changed from 200,000,000 common shares, par value 0.1 per share, to 20,000,000 common shares, par value 1c per share, and the Company's issued and outstanding common shares will be reduced from 53,787,689 to approximately 5,378,769. The Company's common shares will continue to trade on Nasdaq under the symbol "RETO" but will trade under a new CUSIP number - G75271117.nd a vote was not required under the laws of the British Virgin Islands.

08:16 EDT Kerrigan Advisors represents Beck & Matsen in sale of dealerships to Group 1 - Kerrigan Advisors represented Beck & Masten Auto Group in the sale of Beck & Masten Buick GMC North, Buick GMC South and Buick GMC Coastal Bend to Group 1 Automotive. "The dealerships are amongst the highest volume Buick GMC franchises in Texas and the US, ranking as the #1 Buick GMC dealer in Texas for 22 consecutive years and the #1 Buick GMC dealer in the US six times," the company said.

08:13 EDT Soluna Holdings obtains 14 month extension on convertible notes - Soluna Holdings announced an agreement with the holders of its convertible notes to extend the maturity of the notes to July 25, 2024. As consideration for the extension, the Company agreed to pay an extension fee of $250,000, to increase the principal balance of the notes and to issue 6,000,000 new Class A Warrants exercisable at $0.50 and 2,000,000 Class B Warrants exercisable at $0.80. Pursuant to the agreements, the Company has the right, based on market conditions, to require the noteholders to convert up 20% of the outstanding notes. The extension also adds the opportunity for the Company to prepay a portion of the note in cash. Overall, the extension will support the company as it achieves cash flow positive during the second half of 2023 and further monetizes its project pipeline.

08:11 EDT Impel Pharmaceuticals sees Trudhesa delivering 80K-110K TRx for 2023 - The Company continues to project that Trudhesa will deliver prescriptions within the range of 80,000 - 110,000 TRx for full-year 2023.

08:08 EDT Gain Therapeutics expects cash to fund operations into 3Q24 - Cash, cash equivalents and marketable securities were $18.8 million as of March 31, 2023. The Company believes that this amount, together with the proposed research grant funding detailed above and ATM proceeds received in April 2023, will be sufficient to support current operations into the third quarter of 2024.

08:05 EDT Lightning eMotors signs deal with Macnab EV Sales Corp. - Lightning eMotors announced it has signed a contract with Macnab EV Sales Corp. to deliver 126 vehicles to the leading Canadian commercial vehicle distributor by the end of 2023. "It's an honor - and a testament to the quality and reliability of our vehicles - to receive this order from Macnab as they begin their foray into commercial EVs," said Tim Reeser, CEO of Lightning eMotors. "We are proud they chose Lightning vehicles for their customer EV offering and look forward to getting these vehicles into customers' hands this year as we further expand our footprint in Canada." Deliveries of Lightning's ZEV3 vans to Macnab have already begun. The full order of 126 vehicles includes ZEV3 cargo and passenger van configurations and ZEV4 shuttle buses. Macnab has been a leader in the Canadian commercial transportation industry since 1935.

08:04 EDT Landos Biopharma expects cash to fund operations into 1H25 - Cash, cash equivalents and marketable securities were $50.0 million as of March 31, 2023, as compared to $44.4 million on December 31, 2022. The Company expects that its cash position will be sufficient to fund operating expenses and capital requirements into the first half of 2025.

08:02 EDT Zhongchao announces strategic cooperation agreement with Ximalaya - Zhongchao announced that Beijing Zhongchao Boya Medical Technology Co. has signed a strategic cooperation agreement with Shanghai Ximalaya Technology Co., a popular Chinese online audio sharing platform in China. Over the next three years, both parties will work together towards the common vision of "serving a better life through health communications." The cooperation will focus on health knowledge popularization, disease prevention advocacy, and behavioral intervention, gradually improving public health literacy. Pursuant to the cooperation agreement, both parties will integrate and leverage their respective strengths to enhance precision communication in health knowledge popularization. By leveraging the convenience, instant updates, and personalized services and features offered by Ximalaya's online subscription platform, users will receive tailored contents based on their preferences. Boya Medical, utilizing its accumulated experiences in medical education, will provide Ximalaya's users with valuable health and medical information, foster public self-care awareness, and enhance users' disease prevention and control capabilities. The collaboration aims to create a healthy, balanced, and vibrant content ecosystem on Ximalaya's platform. In addition, the collaboration will explore diversified cooperation in intellectual property incubation of streamers focused on health knowledge popularization, copyright development, media operations, and brand co-creations, in order to maximize IP value, and brand value. Furthermore, both parties will research and develop healthcare and wellness care cooperation projects to support each other's business growth.

07:51 EDT Ayr Wellness reaches agreement on GSD NJ, Sira Naturals earn-out amendments - AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) ("AYR" or the "Company"), a leading vertically integrated U.S. multi-state cannabis operator, today announced that it has reached an agreement with Elk Spring Partners, LLC (together with the other selling securityholders under the MIPA (as defined below), the "NJ Counterparties") to amend the earn-out payment terms under the membership interest purchase agreement (the "MIPA") dated as of March 26, 2021, as amended, relating to the Company's acquisition of New Jersey-based GSD NJ, LLC ("GSD"). The earn-out formula and payment terms under the MIPA were amended as follows: The first US$10 million portion of the earn-out will continue to be payable in cash, which payment is expected to be made to the NJ Counterparties by May 19, 2023. The next US$14 million portion of the earn-out, which was to be satisfied by issuing 12.5% promissory notes due September 2024 with interest and principal payments, will instead be satisfied by issuing 13.5% promissory notes due December 2026 with monthly interest-only payments until May 2024. The promissory notes are expected to be issued by May 19, 2023. This amendment results in a meaningful extension of the maturity date and delays repayment of principal, thereby preserving cash on the balance sheet; and The remaining portion of the earn-out, which up to a potential maximum amount of US$72.75 million based on sales of GSD, was to be satisfied by issuing subordinate voting shares based on a 15% discount to the then market price of the SVS, will instead be satisfied by issuing an aggregate of 3,797,468 SVS or shares of CSAC Acquisition NJ Corp. that are exchangeable for SVS at any time or from time to time at the discretion of the holder, at a price equal to US$0.79 per SVS by May 19, 2023; and a cash payment to the NJ Counterparties of approximately US$10.2 million to be made at a future time based on circumstances related to negotiations with other debtholders. This amendment results in a substantial reduction of dilution to the Company's shareholders. In addition, the Company announced today that it has reached an agreement with Green Partners Investor LLC and the other selling securityholders to amend the payment terms under the equity exchange agreement dated as of May 24, 2019, as amended, relating to the Company's Massachusetts-based acquisition of Sira Naturals. The payment terms under the EEA, which were expected to result in a cash payment of US$27.5 million on or before May 1, 2024, has been amended to be paid on the later of the date that is ten calendar days following the maturity date of AYR's 12.5% senior notes due December 10, 2024; or May 1, 2026, but in no event later than December 10, 2026.The unpaid portions of the EEA earn-outs will bear interest at a rate of 6% per annum with 10% annual amortization. The amendment of the EEA earn-out terms results in a material portion of the earn-out payment being deferred until at least May of 2026, thereby preserving cash on the balance sheet. The Company also announced that it has engaged Moelis & Company LLC as its financial advisor to help the Company explore capital structure alternatives to extend upcoming debt maturities.

07:48 EDT Volvo and Jiangling not to pursue acquisition of JMC Heavy Duty Vehicle - Volvo Trucks and Jiangling Motors will not pursue the previously announced transaction involving the acquisition of JMC Heavy Duty Vehicle and its manufacturing site in Taiyuan, Shanxi province, China. The two parties will not pursue the transaction due to that the conditions for closing the transaction were not met. Volvo Trucks will continue to export trucks to customers in China.

07:45 EDT SiriusPoint down 20% after Third Point's Loeb says no longer exploring takeover - Shares of SiriusPoint are down $2.06, or 20%, to $7.90 in pre-market trading following the disclosure from shareholder Dan Loeb of Third Point that he is no longer exploring an acquisition transaction.

07:41 EDT Real Good Food maintains long-term guidance - Sees Net sales of approximately $500M; Adjusted gross margin of 35%; Adjusted EBITDA margin of 15%

07:27 EDT Wearable Devices announces Mudra Band's compatibility with RealWear, Nreal - Wearable Devices announced that the Company's Mudra technology is now compatible with the product lines of two augmented reality glasses manufacturers: RealWear and Nreal. The company said, "RealWear targets the industrial sector with applications across energy and utilities, oil and gas, manufacturing, automotive, and more, and Nreal develops AR glasses targeting a variety of different applications in the consumer space. Over the past few weeks, Wearable Devices has conducted trials in its laboratories and successfully developed a new seamless user experience to control and operate both brands of glasses using intuitive hand gestures with the Mudra Band. RealWear glasses were tested using their built-in industrial application, and Nreal glasses were tested using a mirrored smartphone on the glass's lenses."

07:23 EDT Revive halts Phase 3 study of bucillamine following DSMB recommendation - Revive Therapeutics announced an update on the Company's U.S. Food & Drug Administration Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. On May 10th, 2023, the independent Data Safety Monitoring Board met to review the Study's Post-Dose selection data under the current Study's protocol primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization. The DSMB recommended that the Study be halted early due to statistical significance of the primary endpoint likely not going to be met should the Study continue towards completion. Based on the recommendation from the DSMB, the Company has halted the Study and will now proceed to unblind and seek an evaluation of the Study's data, including the COVID-19 clinical symptoms data to determine the potential next clinical and regulatory steps for Bucillamine. The Company believes that once it has completed the evaluation of the Study's data, it could support further discussions with the FDA on potential new clinical studies and allow the opportunity to work with potential domestic and international pharmaceutical partners to determine a suitable regulatory pathway for approval of Bucillamine based on the evaluated Study's data. The Company is committed to advancing the clinical and commercial development of Bucillamine and plans to pursue the following activities: Continue discussions with the FDA on a pathway for future potential clinical studies for regulatory approval under proposed new efficacy endpoints based on the evaluation of the Study's data; Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for Long COVID or COVID symptom-related conditions and various infectious, inflammatory and respiratory disorders; and Develop reformulation strategies of Bucillamine to expand on its potential therapeutic utility targeting rare disorders that may come with regulatory incentives awarded by the FDA, such as orphan drug, fast track, and breakthrough therapy designations.

07:19 EDT Humacyte expects cash to fund operations past timelines for potential approval - The Company reported cash, cash equivalents and short-term investments of $131.7 million as of March 31, 2023. Subsequent to March 31, 2023, Humacyte reported the completion of an up to $160 million funding arrangement with Oberland Capital. Humacyte believes that its cash, cash equivalents short-term investments and planned funding from the Oberland funding agreement are adequate to fund operations past the anticipated timelines for potential approval and commercialization of the HAV in vascular trauma.

07:15 EDT Centessa expects cash to fund operations into 2026 - Cash, Cash Equivalents and Short-term Investments: $346.2 million as of March 31, 2023, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.

07:07 EDT WisdomTree says Tuckwell, nominees 'wrong' for the company - WisdomTree issued the following letter to its stockholders in connection with WisdomTree's 2023 Annual Meeting of Stockholders, which is scheduled to be held on June 16, 2023. "We are writing again to ask you to protect your investment in WisdomTree and support your Board at the upcoming 2023 Annual Meeting of Stockholders by voting the WHITE proxy card TODAY "FOR" ALL SIX of WisdomTree's highly qualified director nominees - Lynn S. Blake, Daniela Mielke, Shamla Naidoo, Win Neuger, Frank Salerno and Jonathan Steinberg. We urge you to "WITHHOLD" on all three of ETFS Capital's nominees and to NOT sign ANY proxy card or voting instruction form sent to you by ETFS Capital... As we explained in our first letter, dissident stockholder ETFS Capital Limited seeks to elect its chairman Graham Tuckwell and two other unqualified candidates, Bruce E. Aust and Tonia Pankopf, to the WisdomTree Board... Tuckwell's conflicts of interest and documented track record of mistreating stockholders disqualify him from serving on the WisdomTree Board... Courts have found that Tuckwell violated his fiduciary duties as chairman of ETF securities, mistreated minority stockholders and forced out independent directors... Tuckwell recently negotiated against wisdomtree's stockholders and encouraged our largest creditor, the world gold council, to seek a higher price from us solely to justify a higher valuation for himself... Tuckwell has disqualifying and unresolved conflicts of interest that make him unsuitable as a wisdomtree director... Tuckwell's nominees do not bring any new skills or competencies that our collective board does not already possess - our nominees are more capable and better qualified ... Protect your investment in wisdomtree. Reject Graham Tuckwell and vote the white proxy card today "for" all six of wisdomtree's highly qualified candidates WisdomTree stockholders do not need Mr. Tuckwell or his paid nominees to enhance our Board. We have the right strategy and the right Board to oversee it. Your vote for our six director nominees is essential so that we can continue our proven growth strategy and provide the benefits of that strategy to our stockholders.

07:05 EDT Old Republic declares quarterly dividend of 24.5c per share - This dividend is payable on June 15 to shareholders of record on June 5. Subject to Board approval of each quarter's new rate, the full year's cash dividend will amount 98c per share compared to 92c paid in 2022.

07:03 EDT Protagonist and Janssen report data from preclinical studies of JNJ-2113 - Protagonist Therapeutics (PTGX) reported data from its collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)), on Phase 1 and preclinical studies of JNJ-2113, presented by Janssen and co-authored with Protagonist, as an oral presentation at the International Societies for Investigative Dermatology, or ISID, 2023 meeting in Tokyo, Japan. The presentation, "First-in-class oral peptide systemically targeting the IL-23 pathway," is available online at isid2023.org for registered users. Highlights of the data presented on JNJ-2113 include the following: JNJ-2113 is a macrocyclic peptide that binds to the IL-23 receptor with single digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells; although peptides typically have low oral bioavailability, the high potency of JNJ-2113, along with its oral stability, indicated potential for systemic activity beyond the gastrointestinal tract in rat models of inflammation and colitis; In a rat trinitrobenzene sulfonic acid (TNBS)-induced colitis model, efficacy was observed as measured by attenuation of weight loss and colon inflammation with oral doses of JNJ-2113 as low as 0.3 mg/kg/day; In an IL-23-induced rat skin inflammation model, orally dosed JNJ-2113 achieved inhibition of inflammation equivalent to an IL-23 antibody, along with reduction of IL-17 and IL-22 cytokines; Oral treatment with JNJ-2113 provided selective systemic IL-23 pathway inhibition in pre-clinical models that successfully translated to systemic pharmacodynamics activity in healthy human volunteers, indicating potential for JNJ-2113 as a first-in-class oral therapy targeting IL-23-mediated diseases.

07:01 EDT Old Republic announces $450M share repurchase authorization - Old Republic announced its Board of Directors has authorized a $450M share repurchase commencing on the date hereof. This share repurchase authorization is in addition to the recently completed authorization, whereby 19.4M shares of outstanding common stock were purchased at an average price per share of $23.23 for an aggregate cost of approximately $450M.

06:40 EDT Schwazze closes acquisition of two retail dispensaries - Schwazze closed the transaction to acquire certain assets of Cannabis Care Wellness Centers, LLC and Green Medicals Wellness Center #5. The transaction includes the recreational and medical use Smokey's dispensaries located at 2515 7th Avenue in Garden City as well as 5740 S. College Avenue in Fort Collins. These two vibrant cannabis markets have limited licenses and present Schwazze with more opportunities to serve customers in northern Colorado. This acquisition continues Schwazze's deliberate expansion in Colorado, bringing the Company's total number of Colorado dispensaries to 27. The acquired assets included state and local retail marijuana licenses supporting the adult use dispensaries acquired in the transaction. The consideration for the acquisition was $7.5 million paid as a combination of cash and stock.

06:37 EDT Crescent Point Energy sees 2023 average production 160,000-166,000 boe/d - The company said, "Crescent Point's strategic execution in 2023 has significantly enhanced the quality of its asset portfolio and the strength of its financial outlook. The Company now has 15 years of premium drilling inventory, underpinned by its Kaybob Duvernay, Alberta Montney and low-decline assets in Saskatchewan. As previously announced on May 8, 2023, Crescent Point temporarily shut-in approximately 45,000 boe/d of production in the Kaybob Duvernay in response to the recent Alberta wildfires. The Company has now restored 85 percent of this production and continues to monitor the wildfires in Alberta, which have not yet fully stabilized. Crescent Point's 2023 annual average production guidance of 160,000 to 166,000 boe/d, weighted 75 percent to oil and liquids, currently remains unchanged as a result of the Company's strong start to the year. In terms of its budget, Crescent Point has entered into a number of agreements to secure a large portion of its drilling and completions services for the balance of 2023, providing further certainty to its annual program and development capital expenditures guidance, which remains unchanged at $1.15 to $1.25 billion. Crescent Point expects to generate significant excess cash flow in 2023 of approximately $1.1 billion based on its guidance at US$75/bbl WTI. The Company's strong excess cash flow generation is supported by its high-netback asset base and is further enhanced by its significant tax pools. The Company plans to continue to return approximately 60 percent of its excess cash flow to its shareholders, with the remaining portion allocated to its balance sheet. Crescent Point expects to exit the year with a leverage ratio of 1.0 times adjusted funds flow at US$75/bbl WTI and will continue to evaluate non-core dispositions to further strengthen its financial position. The Company is committed to creating long-term value for shareholders by returning capital and continually enhancing the profitability of the business on a per-share basis.

06:34 EDT Spectrum Brands resolves lawsuit with DOJ regarding Assa Abloy - "I am pleased to announce that with the settlement agreement with the DOJ, we have reached a critical milestone in the completion of the sale of our Hardware and Home Improvement business to Assa Abloy (ASAZY) for $4.3 billion in cash. We remain confident that the transaction will close no later than June 30, 2023. We believe that HHI will be better positioned for growth and innovation under Assa Abloy's stewardship, and are excited for our HHI colleagues who have found an excellent home. This is a meaningful strategic pivot for Spectrum Brands (SPB), which will strengthen our balance sheet by making us a net debt free company, and allow us to devote all our resources to and prioritize the long-term growth of our remaining businesses. This transaction will also bring us closer to our long-term goal of becoming a faster growing, higher margin, pure play Global Pet Care and Home & Garden company," said David Maura, Chairman and CEO of Spectrum Brands. Continuing, Maura commented, "On the operating front, while our Global Pet Care and Home and Personal Care businesses performed in line with or better than our expectations, we are disappointed with the results in our Home and Garden business for this quarter. We are facing some additional short-term headwinds as our key retail partners for the Home and Garden categories have continued to reduce inventory in the quarter compared to a typical seasonal build. Based upon the lower first half demand and this further inventory reduction by our retailers, we are lowering our expectations for the year. We now expect our sales in the year to be below consumer demand, which should normalize once we get past the current fiscal year. On the positive side, our renewed focus on profitability, working capital discipline, and cost management continues to pay off as we have reduced our inventory by over $340 million in the last nine months and generated positive free cash flow so far this fiscal year."

06:18 EDT Veracyte announces new data from Prosigna Breast Cancer Assay study - Veracyte announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based study in Norway that is investigating the impact of molecular testing - specifically, the Prosigna test - on breast cancer care and outcomes. These initial data focused on treatment decisions and were shared in a poster at ESMO Breast Cancer Congress 2023, taking place May 11-13 in Berlin. For the study, researchers evaluated data for 2,164 women in Norway with early-stage breast cancer, recording physicians' treatment decisions for these patients before and after a Prosigna test result. Prior to Prosigna results, physicians directed 27% to no systemic treatment, 38% to endocrine therapy only and 35% to chemotherapy followed by endocrine therapy. After Prosigna test results, these treatment decisions changed to 25%, 51% and 24%, respectively. The researchers found that use of Prosigna changed adjuvant therapy decisions for almost one-third of patients. Notably, for patients assigned to chemotherapy prior to Prosigna results, 45% were de-escalated to endocrine therapy following Prosigna results.

06:12 EDT Air Canada sees 2023 ASM capacity up 23% vs. last year - Sees adjusted CASM about 0.5%-2.5% below 2022 levels, sees Adjusted EBITDA about $3.5B-$4B.

06:02 EDT AmerisourceBergen announces common share repurchase from Walgreens Boots Alliance - AmerisourceBergen (ABC) announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings (WBA) in the amount of approximately $50M in concurrence with Walgreens Boots Alliance's entry into certain variable pre-paid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended.

05:56 EDT Walgreens Boots Alliance sells shares of AmerisourceBergen for $694M - Walgreens Boots Alliance (WBA) announced that it has sold shares of AmerisourceBergen (ABC) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 of the Securities Act of 1933, as amended, for current proceeds of approximately $644M. In addition, and subject to the closing of the Rule 144 transaction, Walgreens Boots Alliance entered into a concurrent share repurchase by AmerisourceBergen for proceeds of approximately $50M. Walgreens Boots Alliance's ownership of AmerisourceBergen's common stock has decreased as a result of the concurrent share repurchase by AmerisourceBergen but remains at approximately 17%. Walgreens Boots Alliance's ownership of AmerisourceBergen's common stock has not been impacted by the entry into the variable prepaid forward transactions. The entry into the variable prepaid forward contracts provides Walgreens Boots Alliance with current liquidity while allowing it to maintain voting and dividend rights in the AmerisourceBergen common stock, as well as the ability to participate in potential stock price appreciation during the term of the contracts. The contracts are scheduled to settle starting in the fourth quarter of fiscal year 2025, at which time Walgreens Boots Alliance intends to deliver 4,590,000 shares of AmerisourceBergen common stock in the aggregate to the counterparties to the contracts, and may receive additional proceeds up to $204 million depending on the stock price at the time. Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes.

05:46 EDT Philips to pay more than $62M to settle FCPA charges, SEC says - The SEC on Thursday announced that Amsterdam-based Koninklijke Philips N.V. will pay more than $62M to resolve charges that it violated the Foreign Corrupt Practices Act with respect to conduct related to its sales of medical diagnostic equipment in China. According to the SEC's order, Philips' subsidiaries in China, cumulatively referred to in the order as Philips China, used special price discounts with distributors that created a risk that excessive distributor margins could be used to fund improper payments to government employees. The SEC's order also found that employees, distributors, or sub-dealers of Philips' subsidiaries in China engaged in improper conduct to influence hospital officials to draft technical specifications in public tenders to favor Philips' products. Philips consented to today's SEC order without admitting or denying the findings that it violated the books and records and internal accounting controls provisions of the Securities Exchange Act of 1934, and agreed to pay $15M in civil penalties and more than $47M in disgorgement and prejudgment interest. Reference Link